Description
Background:
Ibalizumab (an entry inhibitor drug) is a non-immunosuppressive humanised monoclonal antibody that binds
CD4, the primary receptor for HIV and inhibits HIV from entering cells. It is a post-attachment inhibitor,
blocking HIV from binding to the CCR5 and CXCR4 co-receptors after HIV binds to the CD4 receptor on the
surface of a CD4 cell.
Intended Use:
For Estimation of Ibalizumab (TROGARZO) in human serum and plasma. Please note the kit has not been optimized to be used for any other animal species. Should you require a specific sera tested, please connect with us at sales@krishgen.com for optimization.
If you have published a paper by using any of our ELISA since 01/01/2023, kindly fill out the “Krishgen Publication Reward Application Form” with complete information and send it by at email: info@krishgen.com, with the subject “Krishgen Publication Reward”. We will get back to you with the Amazon / Krishgen Credit Reward after we confirm it ASAP!